Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib Consolidation for Follicular Lymphoma (FLIPP)
NCT02966730Phase 1Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrutinib in follicular lymphoma (FL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Rate of conversion from FDG-PET positive to negative at 12 months. Started Nov 2016; status: terminated.
02
Drugs
ibrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02966730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966730.